Pregnancy Is No Protection Against Depression Relapse

**BY MARY ANN MOON**

**Contributing Writer**

Washington — There is no evidence that lamotrigine monotherapy increases the risk of major congenital malformations in infants exposed prenatally to the drug, according to updated data from the International Lamotrigine Pregnancy Registry.

The complete interim report contains the following key findings:

- **The rate of malformations among women taking lamotrigine monotherapy was 2.8%**, and the rate among those on polytherapy without valproate was 2.7%.

**Reports also have identified a significantly increased risk of major congenital malformations among women taking valproate as monotherapy.**

Washington — There is no evidence that lamotrigine monotherapy increases the risk of major congenital malformations in infants exposed prenatally to the drug, according to updated data from the International Lamotrigine Pregnancy Registry.

The complete interim report contains the following key findings:

- **The rate of malformations among women taking lamotrigine monotherapy was 2.8%**, and the rate among those on polytherapy without valproate was 2.7%.

**Reports also have identified a significantly increased risk of major congenital malformations among women taking valproate as monotherapy.**

WASHINGTON — There is no evidence that lamotrigine monotherapy increases the risk of major congenital malformations in infants exposed prenatally to the drug, according to updated data from the International Lamotrigine Pregnancy Registry.

The complete interim report contains the following key findings:

- **The rate of malformations among women taking lamotrigine monotherapy was 2.8%**, and the rate among those on polytherapy without valproate was 2.7%.

**Reports also have identified a significantly increased risk of major congenital malformations among women taking valproate as monotherapy.**